Sanofi: Liberum a buyer - good results in ICARIA-MM
(CercleFinance.com) - This morning an analyst at Liberum said that he is maintaining his "buy" rating on the Sanofi stock, in the wake of the pharmaceutical group's positive announcement regarding its ICARIA-PP phase 3 study for patients with relapsed/refractory multiple myeloma.
More extensive date will be unveiled at a conference later this year and filed with regulatory authorities. Liberum however sees this in context: “While the positive read-out is helpful, the indication of third line plus, multiple myeloma is a relatively small commercial opportunity. The remaining P3 studies due to read out over the next 18-24 months are likely to be more commercially relevant.”
As a result, the broker maintains its target price for the share at 82 euros.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
More extensive date will be unveiled at a conference later this year and filed with regulatory authorities. Liberum however sees this in context: “While the positive read-out is helpful, the indication of third line plus, multiple myeloma is a relatively small commercial opportunity. The remaining P3 studies due to read out over the next 18-24 months are likely to be more commercially relevant.”
As a result, the broker maintains its target price for the share at 82 euros.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.